Online citations, reference lists, and bibliographies.
← Back to Search

Antigenic Evolution Of Vaccine-Derived Polioviruses: Changes In Individual Epitopes And Relative Stability Of The Overall Immunological Properties

M. L. Yakovenko, E. Cherkasova, G. Rezapkin, O. Ivanova, A. Ivanov, T. P. Eremeeva, O. Baykova, K. Chumakov, V. Agol
Published 2006 · Medicine, Biology

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
ABSTRACT The Sabin oral poliovirus vaccine (OPV) readily undergoes changes in antigenic sites upon replication in humans. Here, a set of antigenically altered descendants of the three OPV serotypes (76 isolates) was characterized to determine the driving forces behind these changes and their biological implications. The amino acid residues of OPV derivatives that lie within or close to the known antigenic sites exhibited a marked tendency to be replaced by residues characteristic of homotypic wild polioviruses, and these changes may occur very early in OPV evolution. The specific amino acid alterations nicely correlated with serotype-specific changes in the reactivity of certain individual antigenic sites, as revealed by the recently devised monoclonal antibody-based enzyme-linked immunosorbent assay. In comparison to the original vaccine, small changes, if any, in the neutralizing capacity of human or rabbit sera were observed in highly diverged vaccine polioviruses of three serotypes, in spite of strong alterations of certain epitopes. We propose that the common antigenic alterations in evolving OPV strains largely reflect attempts to eliminate fitness-decreasing mutations acquired either during the original selection of the vaccine or already present in the parental strains. Variability of individual epitopes does not appear to be primarily caused by, or lead to, a significant immune evasion, enhancing only slightly, if at all, the capacity of OPV derivatives to overcome immunity in human populations. This study reveals some important patterns of poliovirus evolution and has obvious implications for the rational design of live viral vaccines.
This paper references
10.1016/0092-1157(73)90048-6
History of Sabin attenuated poliovirus oral live vaccine strains
A. Sabin (1973)
10.1159/000149005
Intratypic serodifferentiation of poliomyelitis virus strains by strain-specific antisera.
A. V. van Wezel (1979)
10.1073/PNAS.79.19.5793
Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome.
A. Nomoto (1982)
10.1128/iai.41.3.1217-1225.1983
Natural variation of poliovirus neutralization epitopes
R. Crainic (1983)
10.1073/PNAS.81.5.1539
Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b.
G. Stanway (1984)
10.1093/OXFORDJOURNALS.MOLBEV.A040343
A new method for estimating synonymous and nonsynonymous rates of nucleotide substitution considering the relative likelihood of nucleotide and codon changes.
W. Li (1985)
10.1128/jvi.54.3.856-859.1985
Trypsin sensitivity of the Sabin strain of type 1 poliovirus: cleavage sites in virions and related particles
C. Fricks (1985)
10.1099/0022-1317-67-4-693
Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee.
P. Minor (1986)
10.1128/jvi.57.2.515-525.1986
Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing
N. La Monica (1986)
10.1128/jvi.57.1.81-90.1986
Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site
B. Blondel (1986)
10.1128/jvi.63.12.5354-5363.1989
Construction of less neurovirulent polioviruses by introducing deletions into the 5' noncoding sequence of the genome
N. Iizuka (1989)
10.1016/0042-6822(89)90183-9
Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees.
A. Macadam (1989)
10.1099/0022-1317-70-5-1117
The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3.
P. Minor (1989)
10.1002/j.1460-2075.1989.tb03541.x
Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus.
D. J. Filman (1989)
10.1128/JVI.63.3.1338-1344.1989
Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine
G. Westrop (1989)
10.1099/0022-1317-71-1-43
Localization of genomic regions specific for the attenuated, mouse-adapted poliovirus type 2 strain W-2.
D. Pevear (1990)
10.1007/978-3-642-75602-3_5
Antigenic structure of picornaviruses.
P. Minor (1990)
10.1016/0168-1702(91)90107-7
Detection and identification of vaccine-related polioviruses by the polymerase chain reaction.
C. Yang (1991)
10.1128/jvi.65.10.5225-5231.1991
An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain
A. Macadam (1991)
10.1128/jvi.65.3.1377-1382.1991
Identification of two determinants that attenuate vaccine-related type 2 poliovirus
R. Ren (1991)
10.1128/jvi.66.3.1641-1648.1992
Folding and processing of the capsid protein precursor P1 is kinetically retarded in neutralization site 3B mutants of poliovirus
C. Reynolds (1992)
10.1006/VIRO.1993.1003
Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates.
A. Macadam (1993)
10.1006/VIRO.1994.1353
Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine.
G. Rezapkin (1994)
10.1093/NAR/22.22.4673
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
J. Thompson (1994)
10.1006/VIRO.1995.1268
Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions.
R. Taffs (1995)
10.1128/jcm.33.10.2562-2566.1995
Comparative study of five methods for intratypic differentiation of polioviruses
H. G. van der Avoort (1995)
10.1006/VIRO.1995.1420
Microevolution of type 3 Sabin strain of poliovirus in cell cultures and its implications for oral poliovirus vaccine quality control.
G. Rezapkin (1995)
10.1006/VIRO.1995.0067
Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor.
J. Harber (1995)
10.1016/0168-1656(95)00088-7
Modification of translational control elements as a new approach to design of attenuated picornavirus strains.
V. Agol (1996)
10.1073/PNAS.93.6.2370
Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants.
M. Gromeier (1996)
Manual for the virological investigation ofpoliomyelitis. WHO/EPI/GEN/97.1. World Health Organization
(1997)
10.1128/JCM.36.10.2893-2899.1998
Prolonged Replication of a Type 1 Vaccine-Derived Poliovirus in an Immunodeficient Patient
O. Kew (1998)
10.1006/VIRO.1999.0003
Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient.
A. Bellmunt (1999)
10.1017/S1462399499000848
Poliovirus vaccination: current understanding of poliovirus interactions in humans and implications for the eradication of poliomyelitis.
P. Minor (1999)
10.1073/PNAS.97.1.79
Interaction of the poliovirus receptor with poliovirus.
Y. He (2000)
10.1128/JVI.74.16.7381-7390.2000
Evolution of Circulating Wild Poliovirus and of Vaccine-Derived Poliovirus in an Immunodeficient Patient: a Unifying Model
G. V. Gavrilin (2000)
10.1073/PNAS.97.1.73
Three-dimensional structure of poliovirus receptor bound to poliovirus.
D. Belnap (2000)
10.1128/JVI.74.7.3001-3010.2000
Evolution of the Sabin Strain of Type 3 Poliovirus in an Immunodeficient Patient during the Entire 637-Day Period of Virus Excretion
Javier Martin (2000)
10.1006/VIRO.2000.0462
Expression of mutated poliovirus receptors in human neuroblastoma cells persistently infected with poliovirus.
N. Pavio (2000)
10.1128/JCM.38.10.3729-3734.2000
Molecular and Antigenic Characterization of a Highly Evolved Derivative of the Type 2 Oral Poliovaccine Strain Isolated from Sewage in Israel
L. Shulman (2000)
The scientific basis for stopping polio immunisation--issues and challenges.
D. Wood (2001)
10.1126/SCIENCE.1068284
Outbreak of Poliomyelitis in Hispaniola Associated with Circulating Type 1 Vaccine-Derived Poliovirus
O. Kew (2002)
10.1128/JVI.76.13.6791-6799.2002
Long-Term Circulation of Vaccine-Derived Poliovirus That Causes Paralytic Disease
E. Cherkasova (2002)
Molecular biology of picornaviruses
B. Semler (2002)
10.1128/9781555817916.CH7
Poliovirus Receptors and Cell Entry
J. Hogle (2002)
10.1128/9781555817916.CH30
Poliovirus Vaccines: Molecular Biology and Immune Response
P. Minor (2002)
10.1128/9781555817916.CH29
Determinants of Poliovirus Pathogenesis
M. Gromeier (2002)
Poliovirus genetics: an overview, p. 127–148
V. I. Agol (2002)
Determinants of poliovirus pathogenesis, p. 367–379
M. Gromeier (2002)
Poliovirus receptors and cell entry, p. 71–83
J. M. Hogle (2002)
Poliovirus genetics: an overview
V I Agol (2002)
10.3201/eid0907.020692
Recombinant Vaccine–Derived Poliovirus in Madagascar
D. Rousset (2003)
10.1128/JVI.77.16.8973-8984.2003
Complete Genomic Sequencing Shows that Polioviruses and Members of Human Enterovirus Species C Are Closely Related in the Noncapsid Coding Region
B. Brown (2003)
10.1073/pnas.1633511100
Microarray analysis of evolution of RNA viruses: Evidence of circulation of virulent highly divergent vaccine-derived polioviruses
E. Cherkasova (2003)
10.1128/JVI.77.15.8366-8377.2003
Circulation of Endemic Type 2 Vaccine-Derived Poliovirus in Egypt from 1983 to 1993
C. Yang (2003)
10.1128/JVI.77.8.4827-4835.2003
Complexes of Poliovirus Serotypes with Their Common Cellular Receptor, CD155
Yongning He (2003)
10.1006/VIRO.2002.1736
Characterization of the poliovirus 147S particle: new insights into poliovirus uncoating.
I. Pelletier (2003)
ANTIGENIC EVOLUTION OF VACCINE-DERIVED POLIOVIRUSES 2651 viruses: evidence of circulation of virulent highly divergent vaccine-derived polioviruses
E Cherkasova (2003)
plexes of poliovirus serotypes with their common cellular receptor , CD 155
X. Peng (2003)
10.1038/nrmicro906
Polio eradication, cessation of vaccination and re-emergence of disease
P. Minor (2004)
10.1097/00001756-200402090-00034
A polymorphism in the poliovirus receptor gene differs in motor neuron disease
R. Saunderson (2004)
10.1590/S0042-96862004000100006
Circulating vaccine-derived polioviruses: current state of knowledge.
O. Kew (2004)
10.1128/JVI.78.24.13512-13521.2004
Circulation of Type 1 Vaccine-Derived Poliovirus in the Philippines in 2001
H. Shimizu (2004)
10.1128/JVI.78.9.4876-4883.2004
Characterization of a Highly Evolved Vaccine-Derived Poliovirus Type 3 Isolated from Sewage in Estonia
S. Blomqvist (2004)
10.1086/424524
Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
E. Dragunsky (2004)
10.1128/JVI.78.24.13839-13847.2004
Long-Term Excretion of Vaccine-Derived Poliovirus by a Healthy Child
Javier Martin (2004)
Manual for the virological investigation of poliomyelitis. WHO/IVB/04.10. World Health Organization
(2004)
Manual for the virological investigation of poliomyelitis . WHO / IVB / 04 . 10
C. F. Yang (2004)
10.1586/14760584.4.2.167
ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines
A. Ivanov (2005)
10.1128/JCM.43.6.2886-2894.2005
Genomic Analysis of Vaccine-Derived Poliovirus Strains in Stool Specimens by Combination of Full-Length PCR and Oligonucleotide Microarray Hybridization
M. Laassri (2005)
10.1128/JVI.79.20.12623-12634.2005
Intratypic Recombination among Lineages of Type 1 Vaccine-Derived Poliovirus Emerging during Chronic Infection of an Immunodeficient Patient
C. Yang (2005)
The Scientific Basis for Stopping Polio Immunization
H. Hull (2005)
10.1146/ANNUREV.MICRO.58.030603.123625
Vaccine-derived polioviruses and the endgame strategy for global polio eradication.
O. Kew (2005)
10.1038/434699A
A global call for new polio vaccines
D. Heymann (2005)
10.1016/J.BIOLOGICALS.2004.11.001
Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method.
G. Rezapkin (2005)
10.1016/J.BIOLOGICALS.2004.11.003
Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV).
G. Rezapkin (2005)
10.1128/JVI.79.2.1062-1070.2005
Spread of Vaccine-Derived Poliovirus from a Paralytic Case in an Immunodeficient Child: an Insight into the Natural Evolution of Oral Polio Vaccine
E. Cherkasova (2005)
10.1007/3-540-26397-7_8
Molecular mechanisms of poliovirus variation and evolution.
V. Agol (2006)



This paper is referenced by
10.1016/j.micpath.2020.104603
Amino acid substitutions in VP2, VP1, and 2C attenuate a Coxsackievirus A16 in mice.
Gaobo Zhang (2020)
10.1016/j.vaccine.2020.02.035
Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients.
Sharla L McDonald (2020)
10.3390/v12090970
Case of Poliomyelitis Caused by Significantly Diverged Derivative of the Poliovirus Type 3 Vaccine Sabin Strain Circulating in the Orphanage
E. Korotkova (2020)
OV_A_218494 39..56
Laura N Burga (2019)
10.2147/OV.S218494
Virus–Receptor Interactions: Structural Insights For Oncolytic Virus Development
N. Jayawardena (2019)
10.1016/B978-0-323-35761-6.00048-1
49 – Poliovirus Vaccine–Live
R. Sutter (2018)
10.1128/JVI.01949-17
Dynamics of Evolution of Poliovirus Neutralizing Antigenic Sites and Other Capsid Functional Domains during a Large and Prolonged Outbreak
J. Shaw (2018)
On parechovirus prevalence and pathogenesis
S. E. Karelehto (2018)
10.1038/s41598-017-12458-5
Strain-dependent neutralization reveals antigenic variation of human parechovirus 3
Eveliina Karelehto (2017)
10.1128/JCM.00144-17
Detection of Emerging Vaccine-Related Polioviruses by Deep Sequencing
M. Sahoo (2017)
10.1007/978-1-4939-3292-4_9
Molecular Properties of Poliovirus Isolates: Nucleotide Sequence Analysis, Typing by PCR and Real-Time RT-PCR.
C. C. Burns (2016)
10.1128/JVI.00277-16
A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly Diverged Sabin 2 Vaccine Poliovirus
E. Korotkova (2016)
10.1371/journal.pone.0152251
Molecular and Phenotypic Characterization of a Highly Evolved Type 2 Vaccine-Derived Poliovirus Isolated from Seawater in Brazil, 2014
K. D. M. Cassemiro (2016)
10.1038/srep16728
Virus-like nanostructures for tuning immune response
R. Mammadov (2015)
10.2807/1560-7917.ES2014.19.7.20706
The 2010 outbreak of poliomyelitis in Tajikistan: epidemiology and lessons learnt.
M. Yakovenko (2014)
10.1016/j.antiviral.2014.07.003
H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.
A. Tijsma (2014)
10.1016/j.chom.2013.12.004
Bacterial lipopolysaccharide binding enhances virion stability and promotes environmental fitness of an enteric virus.
C. Robinson (2014)
10.1016/j.jviromet.2013.11.017
Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR.
D. Kilpatrick (2014)
10.1016/B978-1-4557-0090-5.00035-5
28 – Poliovirus vaccine—live
R. Sutter (2013)
10.1007/978-1-4614-5719-0_10
Polio and Its Epidemiology
L. Shulman (2013)
Molecular characterisation of poliovirus inactivation with formaldehyde or other alternative chemical compounds
Thomas Wilton (2012)
10.1586/erv.12.28
Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis
V. Pliaka (2012)
10.1093/infdis/jis204
Common and diverse features of cocirculating type 2 and 3 recombinant vaccine-derived polioviruses isolated from patients with poliomyelitis and healthy children.
M. Joffret (2012)
10.1111/j.1469-0691.2011.03470.x
Retrospective molecular and phenotypic analysis of poliovirus vaccine strains isolated in Greece.
V. Pliaka (2011)
Molecular analysis of persistent enterovirus infections.
Giuseppe Maccari (2011)
10.3390/v3081460
Recombination between Poliovirus and Coxsackie A Viruses of Species C: A Model of Viral Genetic Plasticity and Emergence
Nicolas Combelas (2011)
10.1016/j.vaccine.2010.10.028
Determination of antigenic properties of vaccine derived poliovirus strains.
V. Pliaka (2010)
10.1016/j.jviromet.2010.07.037
Repertoire of antibodies against type 1 poliovirus in human sera.
G. Rezapkin (2010)
10.1016/j.virusres.2010.05.006
Recurrent isolation of poliovirus 3 strains with chimeric capsid protein Vp1 suggests a recombination hot-spot site in Vp1.
S. Blomqvist (2010)
10.1002/rmv.663
Mechanisms of genetic variation in polioviruses
C. Savolainen-Kopra (2010)
10.1128/JVI.02388-08
Shedding of Vaccine Viruses with Increased Antigenic and Genetic Divergence after Vaccination of Newborns with Monovalent Type 1 Oral Poliovirus Vaccine
Sabine M G van der Sanden (2009)
10.1128/JVI.02122-08
Evolution of the Sabin Vaccine into Pathogenic Derivatives without Appreciable Changes in Antigenic Properties: Need for Improvement of Current Poliovirus Surveillance
M. L. Yakovenko (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar